First line therapy in locally advanced or metastatic NSCLC in Asian patients

Provide Superior efficacy in EGFR mutation positive patients

As second line therapy in locally advanced or metastatic NSCLC

As maintenance therapy after first line chemotherapy in patients affected by advanced NSCL